Demet Ozbabalik
Eskişehir Osmangazi University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Demet Ozbabalik.
Journal of Clinical Neuroscience | 2009
Didem Arslantas; Demet Ozbabalik; Selma Metintas; Serhat Özkan; Cemalettin Kalyoncu; Gazi Özdemir; Ali Arslantas
This study aimed to investigate the prevalence of various cognitive disorders in the older population (age 55 years and above) of Eskisehir, Turkey, by conducting a cluster sampled door-to-door survey. A total of 3100 inhabitants were screened with the Mini-Mental State Examination (MMSE) and a questionnaire concerning demographic, occupational and social data. Individuals (n=320) with MMSE scores of 25 were assessed according to the 10th Revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) and were investigated in the more detailed phase 2 study. The overall prevalence of dementia was 8.4%, although it ranged from 2.2% among those aged 55-59 years to 5.3% among those aged 60-64 years, and to 30.4% among those aged 75 or above. Vascular dementia was the most common type (51.1%), followed by Alzheimers dementia (48.8%). In a very small proportion of individuals (0.1%), dementia was due to other causes such as B12 deficiency, a tumour or hydrocephalus. Significant risk factors for dementia were female sex, low education, age, living in a rural area and a family history of dementia.
Neurochemical Research | 2012
Sema Uslu; Zubeyde Eken Akarkarasu; Demet Ozbabalik; Serhat Özkan; Omer Colak; Emine Sütken Demirkan; Ayşe Ozkiris; Canan Demirustu; Ozkan Alatas
Amyloid β42 (Aβ42) and proinflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) have been suggested to contribute to the pathogenesis of Alzheimer’s disease (AD) and vascular dementia (VaD). Our aim was to examine whether the changes in these parameters would be able to discriminate the patients with AD from those with VaD and from healthy individuals. We have analyzed the levels of Aβ42, IL-6 and TNF-α in the serum of newly diagnosed 28 AD patients, 16 VaD patients and 26 healthy non-demented controls. We also investigated whether there is an association between Aβ42, IL-6 and TNF-α levels and mini-mental state examination (MMSE) scores and body mass indexes (BMI) of patients. Our data showed a significant decrease in serum Aβ-42 levels in AD patients compared to VaD patients and controls. Levels of IL-6 and TNF-α were not different between AD patients, VaD patients and controls. We observed a correlation between Aβ-42 levels and MMSE scores and BMI levels in both AD and VaD patients. However, Aβ-42 levels were not correlated with IL-6 and TNF-α levels. Significantly lower levels of Aβ42 found in the serum of AD patients than that of VaD patients and controls suggests that it can be a specific biochemical marker for AD.
Neurological Sciences | 2012
Leman Birdane; Armagan Incesulu; Melek Kezban Gürbüz; Demet Ozbabalik
Alzheimer disease (AD) is a progressive, irreversible entity associated with behavioral changes, memory loss and disturbance of daily life activities. Current diagnostic tools can detect neuronal degeneration in AD only after irreversible damage that already existed. Vestibular evoked myogenic potentials (VEMP) test utilizes the sacculocolic reflex arc and has been used in neuro-otology practice for many years. In this study, we aim to determine if VEMP can be used for diagnostic purposes at the earliest stages of AD. Twenty patients with AD and ten patients with mild cognitive impairment were enrolled in this study. Control group was 30 healthy volunteers with no neurological or otological diseases. Abnormal VEMP responses were found in most of the patients at different stages of AD. VEMP test may be used for early diagnosis of AD. Also, it may provide a novel advancement in understanding of pathophysiology of this disease.
Geriatrics & Gerontology International | 2014
Didem Arslantas; Alaettin Ünsal; Demet Ozbabalik
The present cross‐sectional study was carried out to determine the prevalence of depression among the elderly, and to examine the relationship between depression and dependency in activities of daily living.
Archive | 2012
Demet Ozbabalik; Didem Arslantas; Nese Tuncer Elmacı
Average life expectancy in the world is getting longer in the developing countries as well as developed countries. This means that we will encounter some of the diseases more than diseases which are only seen in elderly, in the coming years. Dementia is one of the most important health problems of the elderly population today, up to the developed countries is seen as a major threat in developing countries. WHO projections suggest that by 2025, about three-quarters of the estimated 1·2 billion people aged 60 years and older will reside in developing countries (1). Thus, by 2040, if growth in the older population continues, 71% of 81·1 million dementia cases will be in the developing world (Figure 1) (2).
Alzheimers & Dementia | 2018
Ceylin G. Sener; Cansu G. Sener; Hulya Ozen; Demet Ozbabalik
amplitude all showed a decrease in the placebo group, whereas they increased in the PQ912 group, indicating an improved global functional connectivity in the latter. The AEC showed a significant effect (mean change: placebo1⁄4-0.0054 versus PQ9121⁄40.0044, t-test: p1⁄40.025, Cohen’s d1⁄40.45) and the TCR-amp showed a trend (mean change: placebo1⁄4-0.0012 versus PQ9121⁄40.0018, p1⁄40.065, d1⁄40.37). The effect measured by AEC remained significant when corrected for sex, country, ApoE, age and baseline value, and additionally for EEG measures of oscillatory activity (global relative power measures in 5 frequency bands; both ANCOVA models p<0.05). There was no correlation between global relative theta power and AEC (r1⁄40.12, p1⁄40.22). Conclusions: Functional connectivity, measured with AEC, significantly improved with PQ912 treatment compared to placebo. This effect sustained when corrected for demographic variables, baseline value and EEG relative power measures.
Alzheimers & Dementia | 2018
Ceylin G. Sener; Cansu G. Sener; Hulya Ozen; Demet Ozbabalik
Background: Roughly 4% of the general population embodies personality, language, and other cognitive traits that characterize a subclinical “broad autism phenotype” (BAP) which qualitatively resembles, but is milder than autism spectrum disorder. Among the normal aging population, individuals with subjective cognitive impairment (SCI) have a high prevalence of psychological distress leading us to predict that BAP would be associated with increasing SCI in the context of otherwise normal aging.Methods: The Autism Spectrum Quotient questionnaire (AQ) is a self-administered 50 item questionnaire whose questions are categorized into five domains comprised of 10 questions each: social skills, attention switching, attention to detail, communication, and ideas. Answers are dichotomized as either agree or disagree. Each item is scored as a “1” if the individual endorses the autistic trait so that scores can range from 0-50. Scores of 23 and above are the threshold for BAP. The AQ was completed by 419 consecutive members of the Arizona APOE Cohort, a longitudinal study of cognitive aging in which participants undergo detailed neuropsychological testing every two years. SCI was assessed with self and informant versions of the Multidimensional Assessment of Neurodegenerative Symptoms questionnaire (MANS). The MANS and auditory verbal learning test (AVLT) scores were standardized in the longitudinal analysis. Results: 45 individuals scored 23 or above and are categorized as AQ+. The remaining 374 are AQ-. The AQ+ group had disproportionately more men (p1⁄4.0005) and a higher proportion of multiple divorces (p1⁄4.01), but no differences in age, education, parental status, occupational status, or income category. All comparisons were corrected for sex. At entry, both MANS-self (p<.0001) and MANS-informant (p<.0001) scores were higher in the AQ+ group despite normal neuropsychological scores. Longitudinally, after age 60, the AQ+ group had a greater annual rate of increase in MANS-self (but not informant) scores (0.05 vs 0.02; diff 1⁄4 0.03; 95%CI: 0.004, 0.05; p1⁄40.02) yet both groups showed only similar mild decline on the AVLTafter age 60 (annual change -0.02 vs -0.02; diff 1⁄4 0.01; 95%CI: -0.01, 0.03; p1⁄40.43) (figure). Conclusions: Within the setting of normal cognitive aging, individuals who meet criteria for the BAP have escalating SCI with age.
Alzheimers & Dementia | 2017
Ceylin G. Sener; Tuna Yelken; Hulya Ozen; Demet Ozbabalik
Urszula Skrobas, Agnieszka Korchut, Katarzyna Grabowska, Sebastian Szklener, Isabel Hernandez, Maitee Rosende-Roca, Ana Mauleon, Liliana Vargas, Monserrat Alegret, Ana Espinosa, Gemma Ortega, Domingo Sanchez, Octavio Rodriguez-Gomez, Angela Sanabria, Alba Perez, Pilar Canabate, Mariola Moreno, Silvia Preckler, Agust ın Ruiz, Konrad Rejdak, Dimitrios Tzovaras, Lluis Tarraga, Merc e Boada, RAMCIPGroup, Fundaci o ACE. Barcelona Alzheimer Treatment & Research Center, Barcelona, Spain; Centre for Research & Technology Hellas/Information Technologies Institute (CERTH/ITI), Thessaloniki, Greece; Medical University of Lublin, Lublin, Poland. Contact e-mail: [email protected]
Annals of General Psychiatry | 2010
Demet İlhan Algin; Alev Kilicoglu; Demet Ozbabalik
UNLABELLED The mild cognitive impairment (MCI), has emerged as an identifiable condition and in many cases is an intermediate state preceding diagnosable Alzheimer disease (AD) characterized by acquired cognitive deficits, without significant decline in functional activities of daily living. The aim of this study was to determine both the presence and type of neuropsychiatric manifestations in MCI patients and to compare them with both those suffering from mild AD and normal controls. METHODS 86 subjects were assessed, 27 were classified as having MCI, 39 as having presumable mild AD, and 20 normal controls matched by age and education. The Neuropsychiatric inventory (NPI-Q) was used to assess the neuropsychiatric manifestations. RESULTS The most common symptoms in the MCI group were irritability (55%), dysphoria (44%), apathy (37%), and anxiety (37%). Statistically significant differences were observed between the MCI and control groups regarding the above mentioned symptoms (p0.05). However, the differences between the MCI and mild AD groups were not found to be statistically significant. CONCLUSION MCI is associated with a high rate of neuropsychiatric symptoms (irritability, depression, anxiety and apathy). These symptoms have serious adverse consequences and should be considered in diagnosis criteria.
Journal of Neurological Sciences-turkish | 2017
Demet İlhan; Suna Atalay Daglı; Serhat Ozkan; Demet Ozbabalik